Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Harnessing CRISPR interference to resensitize laboratory strains and clinical isolates to last resort antibiotics.

Scientific reports - 2 Jan 2025

Frusteri Chiacchiera Angelica, Casanova Michela, Bellato Massimo, Piazza Aurora, Migliavacca Roberta, Batt Gregory, Magni Paolo, Pasotti Lorenzo

Abstract excerpt

The global race against antimicrobial resistance requires novel antimicrobials that are not only effective in killing specific bacteria, but also minimize the emergence of new resistances. Recently, CRISPR/Cas-based antimicrobials were proposed to address killing specificity with encouraging results. However, the emergence of target sequence mutations triggered by Cas-cleavage was identified as an escape...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Bacterial Agents
Share to CRISPR-Cas Systems

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Bacterial

Share to Escherichia coli

Share to Microbial Sensitivity Tests

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 39747289
DOI: 10.1038/s41598-024-81989-5
PMCID: PMC11696610

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 22 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Harnessing CRISPR interference to resensitize laboratory strains and clinical isolates to last resort antibiotics.PMID 39747289Read ↗

Harnessing CRISPR interference to re-sensitize laboratory strains and clinical isolates to last resort antibioticsSemantic proximity Read ↗

CRISPR-Cas Systems in the Fight Against Antimicrobial Resistance: Current Status, Potentials, and Future DirectionsSemantic proximity Read ↗

New frontiers in CRISPR: Addressing antimicrobial resistance with Cas9, Cas12, Cas13, and Cas14Semantic proximity Read ↗

Multidrug-Resistant Enterococci Lack CRISPR- <i>cas</i>Semantic proximity Read ↗

Bacterial resistance to CRISPR-Cas antimicrobials.Semantic proximity Read ↗

Precision Genome Editing Unveils a Breakthrough in Reversing Antibiotic Resistance: CRISPR/Cas9 Targeting of Multi-Drug Resistance Genes in Methicillin-Resistant <i>Staphylococcus aureus</i>Semantic proximity Read ↗

Exploring Clinical Class 1 Integrons as Valuable Targets for the Re-sensitization of Multidrug Resistant Pathogenic Bacteria Using CRISPR-CasSemantic proximity Read ↗

Mobile-CRISPRi: Enabling Genetic Analysis of Diverse BacteriaSemantic proximity Read ↗

CRISPR-Cas. A Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical StudiesSemantic proximity Read ↗

Versatile and Portable Cas12a-mediated Detection of Antibiotic Resistance MarkersSemantic proximity Read ↗

<i>Enterococcus faecalis</i> strains with compromised CRISPR-Cas defense emerge under antibiotic selection for a CRISPR-targeted plasmidSemantic proximity Read ↗

CRISPR-Cas is associated with fewer antibiotic resistance genes in bacterial pathogensSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.